One in three people with cystic fibrosis may experience nephrolithiasis during their life
1. Nearly one in three people with cystic fibrosis experienced nephrolithiasis during their lifetime. 2. The degree of exocrine pancreatic ...
1. Nearly one in three people with cystic fibrosis experienced nephrolithiasis during their lifetime. 2. The degree of exocrine pancreatic ...
Ethosuximide and Irritable Bowel Syndrome–Related Abdominal Pain: A Randomized Clinical Trial 1. Ethosuximide was not superior to placebo for the ...
Key Points: 1. First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data ...
FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis Late last week, the U.S. Food and Drug Administration approved Insmed’s Brinsupri ...
Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
1. In this prospective cohort study, carbonate excretion levels in cystic fibrosis (CF) patients were correlated with various disease severity ...
1. In this retrospective study, newborn screening for cystic fibrosis in the United States lead to improve nutritional status with higher ...
1. This systematic review and meta-analysis demonstrated that higher-than-normal body mass index (BMI) in patients with cystic fibrosis (CF) reduced ...
1. In a prospective multi-center study, 21% of children with cystic fibrosis screen positive, inconclusive diagnosis (CFSPID) at birth were ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.